- Home
- ETW vs COLL Comparison
ETW vs COLL Comparison
Compare ETW & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ETW
Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | ETW | COLL |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ETW | COLL |
|---|---|---|
| Price | $9.26 | $33.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.40 |
| AVG Volume (30 Days) | 222.0K | ★ 384.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $81.73 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $8.28 | $29.08 |
| 52 Week High | $9.60 | $50.79 |
Technical Indicators
Market Signals| Indicator | ETW | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 47.84 |
| Support Level | $9.11 | $31.56 |
| Resistance Level | $9.41 | $35.95 |
| Average True Range (ATR) | 0.09 | 1.20 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 32.98 | 62.20 |
Price Performance
Historical ComparisonAbout ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.